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Background: Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma
(PDAC). Sunitinib (Su) is a novel, multi-target receptor tyrosine kinase inhibitor that has antitumour
activities. This study tested the benefits of combined gemcitabine and sunitinib in PDAC.
Methods: Cell viability and protein expression were evaluated by WST-1 assay and Western blotting.
Tumour growth and survival experiments were performed in murine xenografts.
Results: In PDAC cells, Gem, Su and Su + Gem, respectively, caused 28%, 22% and 48% inhibition in
proliferation at 100 nM. In endothelial cells, Gem, Su and Su + Gem, respectively, caused 49%, 32% and
72% inhibition in proliferation. In fibroblasts, Gem, Su and Su + Gem, respectively, caused 65%, 14% and
79% inhibition in proliferation. Su increased apoptosis, as evidenced by the cleavage of caspase-3 and
PARP-1 proteins. Net tumour growth compared with controls in the Gem, Su and Su + Gem groups was
57%, 6% and 1%, respectively. Intratumoral proliferative activity was reduced by 33%, 82% and 75% in
the Gem, Su and Su + Gem groups, respectively, compared with controls. Median survival in the control,
Su, Gem and Su + Gem groups was 16, 21, 24 and 30 days, respectively (P = 0.007).
Conclusions: These findings support a combination approach using multi-target antiangiogenic agents
such as sunitinib with standard gemcitabine therapy in the treatment of PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most
aggressive humanmalignancies and is characterized by early tissue
invasion and metastasis. Gemcitabine (Gem), a cytotoxic chemo-
therapeutic based on a pyrimidine analogue, is currently the stan-
dard systemic treatment for PDAC, although its clinical benefit
remains marginal.1 The failure of conventional chemotherapy in
PDAC patients emphasizes the urgent requirement for novel and
more effective therapeutic strategies.
Angiogenesis plays a critical role in the progression of primary
and metastatic solid tumours, including PDAC. Several antiangio-
genic agents have been studied in experimental PDAC models,
including anti-vascular endothelial growth factor (VEGF) agents
like bevacizumab, matrix metalloproteinase inhibitors (marimas-
tat) and cyclooxygenase-2 inhibitors (celecoxib), with limited sur-
vival benefit both when used alone and in combination with
chemotherapy.2–4 The epidermal growth factor receptor inhibitor
erlotinib has recently been approved for PDAC treatment in com-
bination with gemcitabine, based on a small but significant
improvement in overall survival.5
Sunitinib (Su) is a multi-target inhibitor of several receptor
tyrosine kinases (RTKs) relevant to tumour angiogenesis, includ-
ing VEGF receptor (types 1, 2, 3) and platelet-derived growth
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factor (PDGF) receptors (a and b).6,7 Sunitinib is currently
approved for the treatment of advanced renal cell carcinoma and
imatinib-resistant gastrointestinal stromal tumours.8,9 The antitu-
mour effects of sunitinib have been partly attributed to its ability
to inhibit tumour angiogenesis.10 Sunitinib has also been shown to
directly inhibit the survival and proliferation of a variety of
cancer cells.6,7,11–13 In human PDAC, VEGF receptors and PDGF
receptors are overexpressed and have been correlated with poor
prognosis.14–16 Recently, sunitinib has been shown to sensitize pan-
creatic cancer to the cytotoxic effects of ionizing radiation17 and,
when administered in combination with metronomic gemcitab-
ine, improved survival in an orthotopic model of pancreatic can-
cer.18 The present study examined the in vitro effects of sunitinib
and gemcitabine on endothelial cell, PDAC cell and fibroblast
proliferation and apoptosis. The in vivo antitumour effects of a
combination therapy with sunitinib and gemcitabine in murine
pancreatic cancer xenograft models were also evaluated.
Materials and methods
Cell culture and reagents
The human pancreatic cancer cell line AsPC-1 and the human
fibroblast cell line WI-38 were grown in RPMI 1640 and DMEM
(Dulbecco’s modified Eagle’s medium), respectively (Sigma
Chemical Co., St Louis,MO,USA), supplemented with 10% foetal
bovine serum and 100 U/ml penicillin/streptomycin solution.
Primary human umbilical vein endothelial cells (HUVECs) were
grown in EndoGRO-LS medium containing endothelial cell
growth supplements (Millipore Corp., Billerica, MA, USA). Gem-
citabine was purchased from Eli Lilly Corporation (Indianapolis,
IN, USA) and sunitinib was purchased from LC Laboratories, Inc.
(Woburn, MA, USA).
Cell proliferation assay
In vitro cell proliferation assays were performed using a colori-
metric WST-1 reagent (Roche Applied Science, Indianapolis, IN,
USA) as previously described.19 This assay is based on the ability of
viable cells to cleave the sulphonated tetrazolium salt WST-1
(4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-
benzene disulphonate) by mitochondrial dehydrogenases. The
cells were placed in a 96-well plate and treated with gemcitabine
and sunitinib, either alone or in combination. After 72 h incuba-
tion, 10 ml of WST-1 reagent was added to each well, and absor-
bance at 450 nmwas measured after 2 h using a microplate reader.
Western blot analysis
A sub-confluent monolayer of cells was treated with gemcitabine
(10 mM) or sunitinib (10 mM) for 16 h. Cells were lysed and equal
amounts of protein were separated by sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to polyvinylidene fluoride (PVDF) membranes (Bio-Rad Labora-
tories, Inc., Hercules, CA, USA). After blocking for 1 h in blocking
solution [5% milk in TBS-T (Tris-buffered saline containing
Tween-20)], the membranes were incubated overnight at 4 °C
with the following antibodies: cleaved poly (ADP-ribose)
polymerase-1 (PARP-1); cleaved caspase-3 (Cell Signaling Tech-
nology, Inc., Beverly, MA, USA) or a-tubulin (Sigma Chemical
Co.). The membranes were then incubated with HRP (horserad-
ish peroxidase)-conjugated secondary antibodies (Pierce Biotech-
nology, Inc., Rockford, IL, USA) for 1 h at room temperature.
Specific bands were detected using the enhanced chemilumines-
cence reagent (ECL) (PerkinElmer Life Sciences, Inc., Boston,MA,
USA) on autoradiographic film and quantitated by densitometry.
Tumour implantation and in vivo tumour
growth experiment
Athymic female nude mice (aged 4–8 weeks) were used for in vivo
tumour growth studies in a subcutaneous xenograft model.
Human pancreatic cancer AsPC-1 cells (0.75 ¥ 106) were injected
subcutaneously in each mouse. After 14 days the animals were
randomly grouped (n = 6–8 per group) and treated intraperito-
neally with phosphate-buffered saline (PBS) (control), sunitinib
(40 mg/kg for 1st week, then 20 mg/kg for 2nd week, in 100 ml
PBS, five times weekly) and gemcitabine (100 mg/kg in 100 ml
PBS, twice weekly), either alone or in combination for 2 weeks.
Doses of gemcitabine and sunitinib were determined according to
the effective and maximum tolerable doses reported in previous
studies.20,21 Tumour size in all mice was measured twice weekly by
calliper. Tumour volume was estimated using the formula [V =
ph(h2 + 3 •2)/6], where V = volume, h = height and • = (length +
width)/2 as previously described.22 Net growth in tumour size was
calculated by subtracting tumour volume on the first day of treat-
ment from that on the last day. After completion of therapy, all
animals were killed and the tumours were excised, weighed, dis-
sected and fixed in 4% paraformaldehyde for histological or
immunohistochemical analysis. The intratumoral proliferative
index (in percent) was determined using a 1 : 200 dilution of Ki67
antibody (Abcam, Inc., Cambridge, MA, USA) and counting the
number of Ki67-positive cells vs. total cells per high-power field
(HPF), averaged from five HPFs within viable tumour areas as
previously described.23 Intratumoral apoptosis was measured by
TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labelling) staining as previously described.24
Animal survival study
In vivo animal survival studies were performed using SCID-NOD
(severe combined immune deficiency, non-obese diabetic) mice
aged 6–8 weeks as previously reported.24,25 Briefly, female SCID
mice were injected intraperitoneally with 0.75 ¥ 106 AsPC-1 cells
in 100 ml serum-free RPMI 1640 medium. Fourteen days after
tumour cell injection, the animals were randomly grouped (n =
6–8 per group) and treated intraperitoneally with PBS (control),
gemcitabine (100 mg/kg in 100 ml PBS, twice weekly) or sunitinib
(40 mg/kg for 1st week, then 20 mg/kg for 2nd week, in 100 ml
PBS, five times weekly), either alone or in combination for 2
weeks. There were no apparent signs of toxicity at these doses.
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Animals were killed when they became moribund. Survival was
evaluated from the first day of treatment until death.
Statistical analysis
Statistical significance was analysed with the two-tailed Student’s
t-test using GraphPad Prism 4 (GraphPad Software, Inc., San
Diego, CA, USA). In vitro cell proliferation assay results are
expressed as the mean  standard deviation. In in vivo studies,
statistical analysis was performed using an analysis of variance
(anova) for multiple group comparisons and Student’s t-test for
individual group comparisons. In survival studies, statistical dif-
ferences were analysed with StatView for Macintosh Version 5.0.1
(SAS, Inc., Cary, NC, USA) by non-parametric survival statistics
and log-rank testing. P-values of <0.05 were considered to repre-
sent statistically significant group differences.
Results
Effects of gemcitabine and sunitinib
on cell proliferation
Within WST-1 in vitro assays on AsPC-1 cells, gemcitabine and
sunitinib inhibited cell proliferation in a dose-dependent manner,
with 45% and 92% inhibition observed at 10 mM, respectively.
Combinations of gemcitabine and sunitinib had additive effects
thatweremore obvious at lower concentrations.At a concentration
of 100 nM, rates of inhibition of proliferation in the Gem, Su and
Su + Gem groups were 28%, 22% and 48%, respectively. In
HUVECs, gemcitabine and sunitinib had greater effects inhibiting
proliferation,with 95% and 88% inhibition at 10 mM, respectively.
The combination of gemcitabine and sunitinib had significant
additive effects, as indicated by the inhibition in proliferation in the
Gem, Su and Su + Gem groups at 100 nM of 49%, 32% and 72%,
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Figure 1 Effects of gemcitabine (Gem) and sunitinib (Su) on in vitro cell proliferation. Cells were plated on 96-well plates and treated with
phosphate-buffered saline [PBS, control (C)], Su (100 nM, 1 mM, 5 mM or 10 mM) or Gem (100 nM, 500 nM, 1 mM or 10 mM), either alone or
in combination. After 72 h, 10 ml WST-1 reagent was added to each well and incubated for a further 2 h. The resulting number of viable cells
was calculated by measuring the absorbance of colour produced in each well. Data represent the mean  standard deviation of
quadruplicate determinants. aP-values of < 0.03 compared with controls
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respectively. In WI-38 cells, inhibition in cell proliferation at the
concentration of 10 mM in the Gem and Su groups was 95% and
87%, respectively. In this cell line gemcitabine was very effective
even at lower concentrations, whereas a proliferation-inhibiting
response to sunitinib was observed only at higher concentrations.
In WI-38 cells, Gem, Su and Su + Gem resulted in inhibition of
65%,14% and 79%, respectively, at 100 nMconcentration (Fig. 1).
Effects of gemcitabine and sunitinib on
apoptosis-related proteins
Expression of protein related to an induction in cellular apoptosis
was evaluated to determine whether the loss of cell viability might
occur by this mechanism.Western blot analysis revealed that in all
three cell lines tested (AsPC-1, HUVECs and WI-38), sunitinib,
either alone or in combination with gemcitabine, caused a signifi-
cant increase in expression of cleaved caspase-3 and cleaved
PARP-1 proteins, indicating the induction of caspase-dependent
apoptosis. No detectable levels of cleaved caspase-3 or cleaved
PARP-1 proteins were observed in gemcitabine treatment alone
(Fig. 2).
Effects of gemcitabine and sunitinib on local
tumour growth
Sunitinib alone was quite effective in inhibiting local tumour
growth in subcutaneous murine PDAC xenografts (Fig. 3).
Gemcitabine alone displayed a moderate inhibitory effect
on local tumour growth, but the combination of Su + Gem
was more effective than either monotherapy. The relative net
tumour growth compared with control referenced at 100% in
the Gem, Su and Su + Gem groups was 57%, 6% and
1%, respectively. Tumour weight at the time of exp-
eriment termination was highly correlated with tumour volume
(r2 = 0.875).
Effects of gemcitabine and sunitinib on intratumoral
proliferative and apoptotic activity
Analysis of intratumoral proliferative activity within tumour
tissue sections showed a significant reduction in Ki67-positive
cells in sunitinib-treated cells consistent with a decrease in the
frequency of dividing cells. Gemcitabine alone caused a small
decrease in Ki67-positive cells. The Su + Gem combination was
effective, but did not enhance intratumoral proliferation inhibi-
tion beyond levels achieved by sunitinib alone (Fig. 4). The Gem,
Su and Su + Gem groups showed reductions in the proliferative
index of 33%, 82% and 75%, respectively, of that in controls.
Increases in TUNEL-positive cells were observed in the Gem and
Su groups. The apoptotic indices (TUNEL-positive cells/total cells
per HPF) in the control, Gem, Su and Su + Gem groups were
0.13 0.03, 0.21 0.06, 0.47 0.05 and 0.54 0.01, respectively
(P < 0.00002 vs. control).
Figure 2 Effects of gemcitabine (Gem) and sunitinib (Su) treatment on cleavage of caspase-3 and PARP-1. A cell monolayer was treated with
Gem (10 mM) or Su (10 mM) for 16 h. Western blot analysis showed the cellular expression of cleaved caspase-3 (18 kda), full-length PARP-1
(116 kDa), cleaved PARP-1 (89 kDa), and loading control a-tubulin (55 kDa). The intensity of bands was quantitated by densitometry and is
represented in the bar graph after normalizing values with a-tubulin expression. Data represent results of two independent experiments in
identical conditions
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Effects of gemcitabine and sunitinib
on animal survival
Animal survival studies performed in AsPC-1 PDAC murine
xenografts in SCID-NODmice resulted in a median survival of 16
days in the control group. This increased modestly after sunitinib
(median: 21 days) and gemcitabine (median: 24 days), but the
Su + Gem combination led to a significant further increase in
survival (median: 30 days; P = 0.007) (Fig. 5).
Discussion
Early metastasis, late-stage diagnosis, high local recurrence risk
and generalized resistance to conventional chemotherapy con-
tinue to impact survival in pancreatic cancer. Gemcitabine repre-
sents the standard cytotoxic agent used in patients with this
disease. However, gemcitabine mediates only limited benefit, both
when administered alone and in combination with other chemo-
therapy agents26–28 or antiangiogenic agents.2–4,29 Tumour growth
is dependent on the complex interaction between multiple com-
ponents, including epithelial tumour cells, endothelial cells and
fibroblasts that are exposed to a milieu of growth factors and
cytokines that probably stimulate multiple signalling pathways
including those that are not inhibited by the therapy adminis-
tered. Combining conventional cytotoxic drugs with novel tar-
geted agents that specifically interfere with key operational
pathways responsible for PDAC progression has recently gained
much attention in the effort to identify a novel, more effective and
less cytotoxic approach to treating PDAC.
Sunitinib is a multi-target RTK inhibitor with antiangiogenic
and antitumour activity.6,7,30 Sunitinib inhibits VEGF receptors,
PDGF receptors, as well as c-KIT, FLT-3 and RET receptors, all of
which can play an important role in tumour progression.10 The
broader target spectrum of sunitinib renders it particularly inter-
esting as an agent in combination therapy, as narrowly defined
tyrosine kinase inhibitors (TKIs) have so far lacked greater clinical
activity. In the present study, the combined effects of gemcitabine
and sunitinib were evaluated in vitro and in vivo. Pancreatic cancer
cell lines display marked heterogeneity towards gemcitabine.31 As
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Figure 3 Effects of gemcitabine (Gem) and sunitinib (Su) treatment on local tumour growth. AsPC-1 cells (0.75 ¥ 106) were injected
subcutaneously into nude mice. At 14 days post-injection, mice were treated with phosphate-buffered saline (PBS, control), Gem or Su,
either alone or in combination, for 2 weeks. (A) Tumour size was measured twice weekly with callipers. (B) Net tumour growth was calculated
by subtracting tumour volume on the first day of treatment from that on the last day. Data represent mean  standard deviation values
(n = 6–8 mice per group)
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PDAC is clinically characterized as very aggressive and highly
resistant to chemotherapy, AsPC-1 cells were used in the present
study because they are only modestly responsive to gemcitabine
in vitro and display a reliable in vivo tumorigenicity. Sunitinib not
only significantly inhibited AsPC-1 cell proliferation, but also
inhibited the proliferation of endothelial cells and fibroblasts.
Modest additive effects were observed for sunitinib administered
in combination with gemcitabine.
These findings indicate that sunitinib affects tumour cells,
endothelial cells and fibroblasts, which supports the proposal that
the antitumour activity of sunitinib may rely on its direct effects
on tumour cells as well as on stromal components including the
tumour vasculature.6,7,10–12 The antitumour activity of sunitinib
has been shown to be accompanied by induction in apoptosis32
and the present findings show that sunitinib administered either
alone or in combination with gemcitabine induced cleaved
caspase-3 and cleaved PARP-1 protein, thereby indicating induc-
tion in apoptosis. In accordance with these in vitro effects, suni-
tinib alone resulted in a significant reduction in local tumour
growth accompanied by a reduction in intratumoral proliferative
activity, indicating that sunitinib obviously has a direct effect on
tumour cells in vivo. Gemcitabine alone also inhibited net tumour
growth and intratumoral proliferative activity and the combina-
tion of Su + Gem was effective, but not significantly more than
sunitinib alone. A recently published report showed that a 1-week
treatment with Su + Gem elicited greater antitumour effects than
either agent administered alone in Pan02 murine xenografts.33
The present study selected a longer therapy interval of 2 weeks,
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Figure 4 Effects of gemcitabine (Gem) and sunitinib (Su) treatment on intratumoral proliferative activity. AsPC-1 cells (0.75 ¥ 106) were
injected subcutaneously into nude mice. At 14 days post-injection, mice were treated with phosphate-buffered saline (PBS, control), Gem
or Su for 2 weeks. (A) Tumour tissue sections were immunostained with Ki67 nuclear antigen antibody and photographed. (B) Ki67-positive
cells were counted per high-power field and the mean counts of five fields were calculated. Data represent mean  standard deviation
values. Significant differences at P < 0.05 compared with the acontrol and bGem groups
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Figure 5 Effects of gemcitabine (Gem) and sunitinib (Su) treatment
on overall mouse survival. AsPC-1 cells (0.75 ¥ 106) were injected
intraperitoneally into SCID mice. At 14 days post-injection, treatment
was started with Gem (100 mg/kg twice weekly) or Su (40 mg/kg for
1st week, then 20 mg/kg for 2nd week) for 2 weeks. Curves repre-
sent survival time from the first day of treatment until death. The
survival difference between the Su + Gem treatment group and the
control group was significant at P = 0.007
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which might lead to an extended progression-free control. The
studies were further extended to observe the effects of the combi-
nation of these agents on actual animal survival. Although the
exact mechanism or optimal combination ability with additional
targeting agents is not yet known, these findings may provide a
foundation for future analyses. The question of whether this com-
bination approach will beneficially affect clinical PDAC therapy
remains open because these results are based on a single cell line
study in a xenograft setting and clinical tumours are expected to
represent a wide spectrum of genetic heterogeneity that may limit
the presence of the susceptibility parameters necessary to mediate
this combination benefit. Defining these markers and validating
them clinically will therefore be an important future undertaking.
Taken together, the results of the present study show that a
combination of gemcitabine and sunitinib can have additive
effects in vitro and in vivo in an experimental pancreatic cancer
model. These findings support the rationale for combining gem-
citabine with multi-target antiangiogenic agents in the search for
a novel and more effective therapy for PDAC.
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